Treatment with MET or the second known AMPK signaling activator, 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), has been shown to reduce tumor growth in p53-deficit HCT116 cells. This evidence concerns the gene TP53 and neoplasm.